TrialsgrambetaRCTs are beautiful

INPULSIS

2014

Nintedanib in Idiopathic Pulmonary Fibrosis

In 1,066 patients with idiopathic pulmonary fibrosis, nintedanib 150 mg twice daily slowed annual FVC decline compared with placebo.

Result

Primary endpoint: Annual rate of FVC decline

-115 vs -240 mL (INPULSIS-1) and -114 vs -207 mL (INPULSIS-2); both p<0.001. Diarrhoea >60%.

Original publication
Subtopic
Antifibrotic: IPF
Design
Two replicate 52-week RCTs
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.doi 10.1056/NEJMoa1402584

Discussion & critique

Anchored FDA approval of nintedanib for IPF.